SKIM Act

House Bill

H.R. 3810

119th Congress

SKIM Act

In Committee

Introduced:Jun 6, 2025

Primary Sponsor

Susie Lee

Representative

Democratic

NV-3

Cosponsors

4

Quick Stats

Policy Area

Health

Summary

The Drug Origin Transparency Act of 2023 would require drug manufacturers to report information about the suppliers of the ingredients used in their products. This includes details on the origin and amount of active ingredients, as well as requiring this information to be included on product labels.

Latest Action

Referred to the Subcommittee on Health.

SponsorSusie Lee (D-NV)

Introduced6/6/2025

StatusReferred to the House Committee on the Judiciary.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

SKIM Act

The Drug Origin Transparency Act of 2023 would require drug manufacturers to report information about the suppliers of the ingredients used in their products. This includes details on the origin and amount of active ingredients, as well as requiring this infor

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The Drug Origin Transparency Act of 2023 would require drug manufacturers to report information about the suppliers of the ingredients used in their products. This includes details on the origin and amount of active ingredients, as well as requiring this information to be included on product labels.

Bill Number: 3810
Sponsor: Susie Lee (D-NV)
Introduced: 6/6/2025
Status: Referred to the House Committee on the Judiciary.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: SKIM Act
Bill Number: 3810
Sponsor: Susie Lee (D-NV)
Status: Referred to the House Committee on the Judiciary.
Introduced: 6/6/2025
Summary: The Drug Origin Transparency Act of 2023 would require drug manufacturers to report information about the suppliers of the ingredients used in their products. This includes details on the origin and amount of active ingredients, as well as requiring this information to be included on product labels.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

The Drug Origin Transparency Act of 2023 would require drug manufacturers to report information about the suppliers of the ingredients used in their products. This includes details on the origin and amount of active ingredients, as well as requiring this information to be included on product labels.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Drug Origin Transparency Act of 2023 This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Key Points

Main provisions of the bill

Drug manufacturers must report detailed information about their supply chain, including the suppliers of active ingredients and the amounts used.
Manufacturers must include information about the origin of ingredients on the labels of their drug products.
The goal is to provide more transparency around the sources of drugs and their components.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would impact drug manufacturers and consumers. Consumers would have more information about where the drugs they take come from. Drug companies would need to track and disclose their supply chain details, which could increase their administrative costs. Overall, the bill aims to shed light on the global pharmaceutical supply chain.

Policy Areas

Primary Policy Area

Health

Related Subjects

Consumer affairs

Government information and archives

Manufacturing

Prescription drugs

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

3810, 119th Congress (2025). "SKIM Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3810

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.